



Figure S6. Images of immunostaining for BAF250a. Immunostaining was performed to examine the expression of BAF250a in A, ovarian clear cell carcinoma and B, uterine endometrium. While BAF250a staining was positive in uterine endometrium, which harbored the splice site SNV (c.4993+2T>C) in *ARID1A*, it was negative in ovarian clear cell carcinoma, which harbored both the splice site SNV and the frameshift insertion (p.E1683fs) in *ARID1A*. These FFPE tissues were from locations near those used for laser microdissection sampling. The antibody used for the experiment was HPA005456 (Sigma-Aldrich, St. Louis, USA). The scale bars represent 100 μ m.